ROYAL PARK PARTNERS ADVISES SPEECHMATICS ON ITS  SERIES B FUNDING ROUND, RAISING $62 MILLION LED BY SUSQUEHANNA GROWTH EQUITY

Overview of the transaction

Speechmatics, one of the industry leaders in Autonomous Speech Recognition (“ASR”), has announced its $62m Series B funding round led by funds managed by Susquehanna Growth Equity.

 

Existing investors IQ Capital and AlbionVC also participated in the round.

 

The funding will be used to further develop Speechmatics’ unique learning models and improve accuracy, invest in technology and business development, while enabling Speechmatics to exceed the demands of its fast-expanding enterprise customer base.

Overview of Speechmatics

  • Founded in 2006 and based in Cambridge, UK, Speechmatics has built a market-leading technology, based on selfsupervised neural networks. Speechmatics’ ASR allows companies to leverage the power of unstructured data, facilitating a seamless human-to-machine interaction for everyone

  • Its next-generation self-supervised learning models can exploit millions of hours of unlabeled audio, building new models with 100x less labeled data to achieve the same accuracy, delivering the most accurate, flexible and inclusive speech-to-text on the market

  • Speechmatics’ market leading ASR capabilities have attracted many blue-chip customers across various verticals including what3words, 3Play Media, Veritone, Deloitte UK and Vonage

Royal Park Partners' role

  • Royal Park Partners acted as exclusive financial and strategic advisor to Speechmatics and its shareholders throughout the transaction.

  •  This transaction highlights Royal Park Partners’ extensive experience in the deep tech and SaaS space servicing financial services companies.

Disclaimer

This presentation may not be disseminated, distributed or used without the prior written consent of Royal Park Partners and Sapia Partners LLP (the “Companies”). The information contained in
the Presentation is not intended to be viewed by, passed on or distributed (directly or indirectly) to, any other category of persons. Royal Park Partners is an Appointed Representative of
Sapia Partners LLP, which is authorised and regulated by the Financial Conduct Authority.


No undertaking, representation, warranty or other assurance is given, and none should be implied, as to, and no reliance should be placed on, the accuracy, completeness or fairness of the
information or opinions contained in the Presentation. The information contained in the Presentation is subject to completion, alteration and verification nor should it be assumed that the
information in the Presentation will be updated. The information contained in the Presentation has not been verified by Sapia Partners LLP (“Sapia”) or any of its associates or affiliates.


Opinions and estimates constitute the Companies’ judgment and should be regarded as indicative, preliminary, strictly non-binding and for illustrative purposes only. All example statements
and any indicative terms and features of any solution given are strictly indicative and may be based on certain implicit and explicit assumptions which the Companies may or may not be
able to disclose at the time of the Presentation and which will need verification in any specific case.


In particular, but without prejudice to the generality of the foregoing, any forecasts, opinions, estimates and projections contained in the Presentation constitute the judgement of the
Companies and are provided for illustrative purposes only. Such forecasts, opinions, estimates and projections involve known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forecasts, opinions,
estimates and projections. Accordingly, no representation or warranty (express or implied) is or will be made or given in relation to, and (except in the case of wilful fraud) no responsibility or
liability is or will be accepted by the Companies or any of its directors, officers, employees, agents or advisers in respect of, such forecasts, opinions, estimates and projections or their
achievement or reasonableness. Persons of the Presentation must determine for themselves the reliance (if any) that they should place on such forecasts, opinions, estimates and projections.
Further, no representation as to the actual value which may be received in connection with a transaction is given, nor the legal, tax or accounting effects of consummating a transaction.


Information contained in the Presentation may not be distributed, published or reproduced in whole or in part or disclosed by Persons to any other person. The distribution of any document
provided at or in connection with the Presentation in jurisdictions other than the United Kingdom may be restricted by law and therefore persons into whose possession any such documents
may come should inform themselves about and observe any such restrictions. In particular, information contained within the Presentation is not for distribution in or into the United States,
Canada, Australia, the Republic of Ireland, Japan or South Africa. Any failure to comply with these restrictions may constitute a violation of the securities law of such jurisdictions.


The information contained in the Presentation has not been approved by the Financial Conduct Authority. This Presentation does not constitute, or form part of, any offer of, or invitation to
apply for, securities nor shall it, or the fact of its distribution, form the basis of or be relied upon in connection with any contract or commitment to acquire any securities. The information
contained in the Presentation has been prepared to assist Persons in making their own evaluations and does not purport to contain all of the information that recipients of the Presentation
who are considering acquiring or subscribing for shares, bonds or other securities may need or desire. In all cases, Persons should conduct their own investigation and analysis of the data in
the Presentation. The Presentation should not be considered a recommendation by the Companies’ or any of its directors, officers, employees, agents or advisers in connection with any
purchase of or subscription for securities.